Generic semaglutide can reduce the cost barrier, but the overall treatment quality still depends on the brand, dose schedule, device type and clinical follow-up
GLP-1 RAs show potential benefits in improving MASLD across multiple dimensions with a relatively acceptable safety profile, but nearly 80% of included reviews are of critically low quality with high evidence overlap
If your Aetna plan denies coverage for Wegovy, you can request an appeal by the due date
Most patients see steady, manageable weight loss over the first 12 weeks, especially when they combine the medication with healthy eating, movement, and consistent support
Language: ENGLISH: DTS-HD Master Audio 5.1 (48kHz, 24-bit)
NHS England and the Department of Health and Social Care have issued guidance prioritising existing patients and those with greatest clinical need